US2021401850A1PendingUtilityA1

Antiviral therapy

71
Assignee: VIIV HEALTHCARE COPriority: Jan 27, 2010Filed: Sep 8, 2021Published: Dec 30, 2021
Est. expiryJan 27, 2030(~3.5 yrs left)· nominal 20-yr term from priority
Inventors:Mark Richard Underwood
A61K 31/5365A61K 9/0019A61K 31/536A61K 31/675A61P 37/04A61K 31/52A61P 31/18A61P 31/12A61K 31/513A61K 31/4985A61K 9/0014A61K 2300/00A61K 45/06A61K 31/505A61K 9/0053A61P 43/00A61P 31/00A61K 2121/00
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a combination comprising (3S, 11aR)—N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine, along with therapeutic methods administering the same.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A combination comprising (3S, 11aR)—N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo [3,2-a] pyrido [1,2-d]pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine. 
     
     
         2 . A method of treatment of HIV infection comprising administering to a human (3S, 11aR)—N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof, with rilpivirine. 
     
     
         3 . The method according to  claim 2 , wherein the compounds are administered simultaneously. 
     
     
         4 . The method according to  claim 2 , wherein the compounds are administered sequentially.

Join the waitlist — get patent alerts

Track US2021401850A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.